Sichuan Baili Pharmaceutical Co., Ltd.

This study tests a combination of two or three drugs (BL-B01D1, pembrolizumab, and possibly bevacizumab) in people whose cervical or endometrial cancer has returned or spread. The goal is to see if these drugs can shrink tumors or slow the disease. About 96 adults aged 18–75 with…

This study is testing a new combination of two drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced head and neck cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the treatment can shrink tumors. A…

This study tests a new drug called BL-B01D1 against standard chemotherapy in 384 adults with ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based treatment. The goal is to see if BL-B01D1 can slow cancer growth and improve survival. Pa…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in 100 people with extensive-stage small cell lung cancer that has not responded to prior treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Participants mus…

This study tests a new drug called GNC-035 for people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is a special antibody designed to attack cancer cells from multiple angles. The trial has two parts: first, finding the safest dose, and…

This early-phase study tests a new drug called BL-B16D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 21 adults aged 18 to 75 will take par…

This early-phase study tests a new radioactive drug called Lutetium BL-ARC001 in 22 adults with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have …

This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. The goal is to see if BL-M07D1 can slow cancer growth or improve survival. Participants are randomly assigned to re…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in 52 adults with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Parti…

This study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer (urothelial carcinoma) that has worsened after prior treatments. About 508 adults whose cancer did not respond to platinum chemo and immunotherapy will be randomly as…

This early-phase study tests a new drug called BL-M11D1 in 130 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can help control the disease. Participants mu…

This early-phase study tests a new drug called BL-M17D1 in about 20 people with advanced HER2-positive or low-HER2 cancers of the digestive tract (esophagus, stomach, pancreas, colon) and other solid tumors. The main goals are to check safety, find the best dose, and see if the d…

This study tests an experimental drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants will be monitored for sid…

This phase 3 study tests whether adding the experimental drug BL-B01D1 to the standard targeted therapy osimertinib works better than osimertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 720 adults with locally advanced or metasta…

This early-phase study tests a new drug called GNC-077 in about 20 people with advanced lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have a tumor that can …

This study tests three experimental treatments for people with advanced esophageal, stomach, or colorectal cancers that have spread. The goal is to see if these drug combinations can shrink tumors and how safe they are. About 376 adults aged 18 to 75 will participate. The treatme…

This study tests two experimental drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced non-small cell lung cancer. The goal is to find a safe dose and see if the treatment shrinks tumors. About 160 adults aged 18 to 75 who have not responded to prior …

This early-phase study tests a new drug called GNC-077 in 20 people with advanced breast cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have a tumor that can be measu…

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This early-phase study tests a new drug called BL-B16D1 in people with head and neck cancer or other solid tumors that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 21 adults who have not resp…

This early-phase study tests a new drug called BL-M07D1 in 26 adults with advanced digestive tract or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participa…

This early-stage study tests a new drug called GNC-039 in about 60 people with brain tumors (glioma) or other solid cancers that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have tr…

This study tests a new drug called BL-M07D1, with or without another drug (pertuzumab), against standard chemotherapy for HER2-positive breast cancer before surgery. About 120 women with stage II or III breast cancer will take part. The goal is to see if the new combination can c…

This early-phase study tests a new drug called BL-M17D1 in about 20 adults with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants…

This study tests a new drug (BL-B01D1) combined with a standard targeted therapy (TKI), with or without an immunotherapy (pembrolizumab), in 260 adults with advanced kidney cancer that has spread. The goal is to see if these combinations shrink tumors and are safe. Participants m…

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 who have already t…

This study tests a new drug called BL-B01D1 in 38 adults with advanced gynecological or other solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. Researchers will also monitor side effects clos…

This early-phase study tests a new radioactive drug (lutetium [177Lu]-BL-ARC001) in 22 adults with advanced lung, breast, head/neck, or other solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This study compares a new drug, BL-M07D1, to standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific HER2 gene change. About 440 adults will be randomly assigned to one of the two treatments. The goal is to see if the new drug helps peopl…

This study tests a new drug called BL-M07D1 in 42 adults with advanced HER2-positive or HER2-low urinary and digestive tract cancers that cannot be removed by surgery. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. The goal is to contr…

This early-stage study tests a new drug called BL-M08D1 in people with blood cancers (lymphoid malignancies) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Abou…

This study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that has a specific marker (HER2-positive) and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-…

This early-phase study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have spread and no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, a…

This early-phase study tests a new drug called BL-M08D1 in about 22 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the …

This study tests a new combination of drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this combination can shrink tumors and delay cancer growth. About 60 adults aged 18 to…

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1,450 women aged 18-75 will be randomly assigned to one of the two tr…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced HER2-negative breast cancer that has spread or cannot be removed. The goal is to see if these treatments can shrink tumors or slow the disease. About 58 adults who have not r…

This early-phase study tests a new drug called BL-B01D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 570 participants will be enrolled to also see if the drug can shri…

This study tests an experimental drug called BL-M07D1 in women with recurrent or metastatic gynecologic cancers that have a specific marker called HER2. The goal is to find the best dose and see if the drug can shrink tumors. About 138 participants will receive the drug, and rese…

This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 adults will take part to see if the drug can h…

This study tests whether combining two drugs, BL-M07D1 and pembrolizumab, can shrink tumors in people with advanced HER2-positive non-small cell lung cancer. About 80 adults with cancer that has spread or cannot be removed by surgery will receive the treatment. The goal is to see…

This early-phase study tests a new drug called BL-M24D1 in 16 people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must be 18 or older and have t…

This early-phase study tests a new drug, BL-M07D1, in about 26 adults with advanced HER2-positive or HER2-low breast cancer or other solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and get an early look at …

This early-phase study tests a new drug called BL-B01D1 in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 to 75 will take part.

This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participant…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in 130 women with recurrent or metastatic cervical cancer that has not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Participants …

This early-phase study tests a new drug, BL-M24D1, in people with advanced digestive tract or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 33 adults will take part in this non-randomized tr…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This study tests a new drug called GNC-038, a special antibody that targets cancer from four different angles. It is for people with Non-Hodgkin's lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find …

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced non-small cell lung cancer or nasopharyngeal carcinoma that has spread. The main goal is to see if the treatment is safe and if it shrinks tumors. Researchers will enroll about 121 adul…